Hasil Pencarian - Zeynep Eroglu

Perbaiki Hasil
  1. 1
    Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy

    Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy oleh Zeynep Eroglu, Antoni Ribas

    Diterbitkan 2016-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Investigation of the Changes in Rheological Properties of Purple Basil Sherbet Samples Concentrated by Ohmic Heating at Different Voltage Gradient

    Investigation of the Changes in Rheological Properties of Purple Basil Sherbet Samples Concentrated by Ohmic Heating at Different Voltage Gradient oleh Zeynep Eroğlu, Mutlu Çevik

    Diterbitkan 2022-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Combination targeted and immune therapy in the treatment of advanced melanoma: a valid treatment option for patients?

    Combination targeted and immune therapy in the treatment of advanced melanoma: a valid treatment option for patients? oleh Shahla Bari, Jameel Muzaffar, Zeynep Eroglu

    Diterbitkan 2022-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    The emergence of neoadjuvant therapy in advanced melanoma

    The emergence of neoadjuvant therapy in advanced melanoma oleh James Sun, Dennis A Kirichenko, Jonathan S Zager, Zeynep Eroglu

    Diterbitkan 2019-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma

    A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma oleh Joseph Markowitz, Ragini Kudchadkar, Jeffrey S. Weber, Zeynep Eroglu, Andrew S. Brohl, Nikhil I. Khushalani, Ram Thapa, Y. Ann Chen

    Diterbitkan 2016-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Role of SMC1 in overcoming drug resistance in triple negative breast cancer.

    Role of SMC1 in overcoming drug resistance in triple negative breast cancer. oleh Sushma Yadav, Archana Sehrawat, Zeynep Eroglu, George Somlo, Robert Hickey, Sailee Yadav, Xueli Liu, Yogesh C Awasthi, Sanjay Awasthi

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Quality of life and patient‐reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body radiation therapy

    Quality of life and patient‐reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body rad... oleh Aasha I. Hoogland, Andrew S. Brohl, Brent J. Small, Lauren Michael, Evan Wuthrick, Zeynep Eroglu, Dukagjin Blakaj, Claire Verschraegen, Nikhil I. Khushalani, Heather S. L. Jim, Sungjune Kim

    Diterbitkan 2024-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    797 Significant anti-tumor activity of HBI-8000, a class I histone deacetylase inhibitor (HDACi) in combination with nivolumab (NIVO) in anti-PD1 therapy-naïve advanced melanoma (TN-Mel)

    797 Significant anti-tumor activity of HBI-8000, a class I histone deacetylase inhibitor (HDACi) in combination with nivolumab (NIVO) in anti-PD1 therapy-naïve advanced melanoma (T... oleh Joseph Markowitz, Siqing Fu, Gregory Daniels, Lyudmila Bazhenova, Nikhil Khushalani, Zeynep Eroglu, Andrew Brohl, Heather Yeckes-Rodin, Lori McCormick, Michael Kurman, Mireille Gillings, Gloria Lee

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction

    Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction oleh Igor Puzanov, Suthee Rapisuwon, Leora Horn, Bridgette A. Kanz, Megan H. Pollack, Romany Johnpulle, Alicia Morgans, Jeffrey A. Sosman, R. Martin Conry, Zeynep Eroglu, Douglas B. Johnson

    Diterbitkan 2016-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Drepmel—A Multi-Omics Melanoma Drug Repurposing Resource for Prioritizing Drug Combinations and Understanding Tumor Microenvironment

    Drepmel—A Multi-Omics Melanoma Drug Repurposing Resource for Prioritizing Drug Combinations and Understanding Tumor Microenvironment oleh Zachary J. Thompson, Jamie K. Teer, Jiannong Li, Zhihua Chen, Eric A. Welsh, Yonghong Zhang, Noura Ayoubi, Zeynep Eroglu, Aik Choon Tan, Keiran S. M. Smalley, Yian Ann Chen

    Diterbitkan 2022-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma

    Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma oleh Joseph Markowitz, Ahmad A Tarhini, Zeynep Eroglu, Evan J Wuthrick, Andrew S Brohl, Nikhil I Khushalani, Vernon K Sondak, Lilit Karapetyan, Tanya Ramadoss, Matthew Nichols, Christian Palacios, Kenneth Y Tsai

    Diterbitkan 2024-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Health‐related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 trial

    Health‐related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 trial oleh Ketty Peris, Timothy J. Inocencio, Alexander J. Stratigos, Karl D. Lewis, Zeynep Eroglu, Anne Lynn S. Chang, Cristina Ivanescu, Aleksandar Sekulic, Matthew G. Fury, Chieh‐I Chen, Ruben G. W. Quek

    Diterbitkan 2024-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours

    BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours oleh Zeynep Eroglu, Joe Ensor, Meenakshi Malhotra, Paul Billings, Angel Rodriguez, Alexey Aleshin, Ling Gao, Sarah Sawyer, Pashtoon Murtaza Kasi, Sascha Ellers, George Ansstas, Michael Krainock, Sakti Chakrabarti, Andrew Poklepovic, Minu Maninder

    Diterbitkan 2022-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    596 AMBER, Part 2B: a phase 1 study of cobolimab plus dostarlimab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with anti-PD(L)-1 therapy

    596 AMBER, Part 2B: a phase 1 study of cobolimab plus dostarlimab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with anti-PD(L)-1 thera... oleh Antoni Ribas, Mohammed Milhem, Diwakar Davar, Patricia LoRusso, Zeynep Eroglu, Martin Gutierrez, Arindam Dhar, Carlos Becerra, Brian Di Pace, Tianli Wang, Hailei Zhang, Srimoyee Ghosh, Shyam Srivats, Theo Borgovan, Angela Waszak

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    312 Female sex independently predicts adjuvant immunotherapeutic benefit from CTLA4 immune checkpoint inhibition

    312 Female sex independently predicts adjuvant immunotherapeutic benefit from CTLA4 immune checkpoint inhibition oleh Gary Cohen, Omid Hamid, Lawrence Flaherty, Henry Koon, Jeffrey Sosman, David Minor, Zeynep Eroglu, John Kirkwood, F Stephen Hodi, Donald Lawrence, Ni Kang, Sandra Lee, Laura Hutchins, Harriett Kluger, Kari Kendra, Carrie Lee, Mark Albertini, Teresa Petrella, Howard Striecher, Vernon Sondak

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    625 Immune priming IFx-Hu2.0 promotes antibody responses necessary for anti-PD1 responses in PD-1 refractory melanoma patients

    625 Immune priming IFx-Hu2.0 promotes antibody responses necessary for anti-PD1 responses in PD-1 refractory melanoma patients oleh Joseph Markowitz, Shari Pilon-Thomas, Amod A Sarnaik, Pei-ling Chen, Ahmad A Tarhini, Zeynep Eroglu, Andrew S Brohl, Nikhil I Khushalani, Vernon K Sondak, Youngchul Kim, Michael Shamblott, Christopher W Dukes, Alejandra Chamizo, Marina Bastawrous, Edward Garcia, Ashraf Delhawi, Deanryan BDe Aquino, Patricia Lawman

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy

    Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy oleh Wei Wang, Andrew Haydon, Rebecca Johnson, Elisabeth Livingstone, Zeynep Eroglu, Grant A McArthur, Douglas B Johnson, Prachi Bhave, Georgina Long, Adnan Khattak, Matteo S Carlino, Johanna Mangana, Katharina Kahler, Angela Hong, Serigne N Lo, Hui-Ling Yeoh, Alexander Maxwell Menzies, Ozgecan Dulgar, Georg C Lodde, Axel Hausschild

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanomaResearch in context

    Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanomaResearch in context oleh Inna Smalley, Eunjung Kim, Jiannong Li, Paige Spence, Clayton J. Wyatt, Zeynep Eroglu, Vernon K. Sondak, Jane L. Messina, Nalan Akgul Babacan, Silvya Stuchi Maria-Engler, Lesley De Armas, Sion L. Williams, Robert A. Gatenby, Y. Ann Chen, Alexander R.A. Anderson, Keiran S.M. Smalley

    Diterbitkan 2019-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma

    Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma oleh Judith D Goldberg, Joseph Markowitz, Jeffrey Weber, Ragini Kudchadkar, Tomas Kirchhoff, Anna Pavlick, Zeynep Eroglu, Melinda Vassallo, David M Woods, Andrew S Brohl, Nikhil I Khushalani, Alison Richards, Younchul Kim, Biwei Cao, Robert Ferguson, Kelsey R Monson, Carol M Amato, Paulo Burke, Ann Strange, Emily Monk, Geoffrey Thomas Gibney

    Diterbitkan 2022-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer

    Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer oleh Christopher A Barker, Evan J Lipson, Harriet Kluger, Brian R Gastman, Michael T Tetzlaff, Igor Puzanov, Shailender Bhatia, Paul Nghiem, Ann W Silk, Zeynep Eroglu, Sunandana Chandra, Isaac Brownell, Anna C Pavlick, David M Miller, Vernon K Sondak, Kari L Kendra, Kathryn B Bollin, Kathleen Madden, Guilherme Rabinowits, Emily S Ruiz, Edward A Tavss

    Diterbitkan 2022-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: